American Academy of Ophthalmology 2026
CLOSE
MENU
  1. Home
  2. ›
  3. HCPs
  4. ›
  5. Previous Congress Materials
  6. ›
  7. Congress Detail

American Academy of Ophthalmology (AAO) 2026


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

American Academy of Ophthalmology (AAO) 2026


Content provided by Bausch + Lomb Global Medical and Scientific Affairs.

Summary

The world's largest ophthalmology congress, bringing together more than 16,000 eye care professionals across the full spectrum of clinical and surgical practice. Bausch + Lomb presented seven scientific posters across surgical and prescription portfolios. Communications highlighted enhanced monofocal and small-aperture IOLs (enVista Aspire™, IC-8® Apthera™), implant-free glaucoma surgery (ELIOS™), and dry eye treatment (MIEBO®, XIIDRA®).

Abstracts

BACKGROUND: Daily disposable soft contact lenses are an important alternative to frequent replacement lenses for patients who may benefit from improved comfort and convenience. This case series aimed to understand real-world experiences of patients transitioning from frequent replacement to daily disposable lenses, here with nesofilcon A as an introductory lens to this new modality. Cases were collected as part of a wider study with central institutional board exemption.

CASE SUMMARY: We present patients from six separate sites who transitioned from frequent replacement lenses to nesofilcon A daily disposable lenses (B+L Biotrue ONEday). This case series included six female and four male patients (20 eyes) who were 19–62 years of age when presenting for refitting; nine were White and one did not report race. With habitual correction, distance best-corrected visual acuity (BCVA) OU was 20/20 for seven (70.0%) patients and 20/25 for one (10.0%) patient with the frequent replacement lenses, 20/30 for one (10.0%) patient with spectacles, and not reported for one patient. Reasons for fitting with nesofilcon A daily disposable lenses included requiring improved comfort, convenience, visual stability, and ocular health; discouraging lens overwear; decreasing allergy signs and symptoms; and patient request to switch to dailies or to have the option for seasonal/vacation use. Five patients (nine eyes) were fit with spherical lenses and six patients (eleven eyes) were fit with toric lenses. A successful fit was achieved for all cases, with good lens centration and movement. At initial fit, distance BCVA OU was 20/15−1 for one (10.0%) patient, 20/20 for seven (70.0%) patients, 20/20−2 for one (10.0%) patient, and not reported for one (10.0%) patient. For most patients, prescription remained the same over the course of documented follow-up (1 week–10.5 years). At most recent follow-up, distance BCVA OU was 20/20 for nine (90.0%) patients and 20/20−1 for one (10.0%) patient.

CONCLUSION: Transitioning from frequent replacement lens wear to nesofilcon A daily disposables was associated with good visual acuity outcomes and acceptable lens fit. Overall, these findings support nesofilcon A lenses as a suitable option for patients wearing frequent replacement lenses and open to moving to a daily disposable.

Purpose: Evaluation of visual and refractive outcomes following IC-8 intraocular lens (IOL) implantation in patients with corneal irregularities.

Methods: Records of 25 cataract eyes with prior corneal refractive surgery or corneal comorbidities implanted with IC-8 IOL were retrospectively reviewed. Of them, 52% had prior LASIK, 36% prior RK, 8% keratoconus, and 4% post-PRK ectasia.

Results: Postoperatively, all eyes had CDVA of 20/32 or better. With a mean MRSE of -0.35±0.61 D and UDVA of 0.16±0.14 logMAR, 80% had UDVA of 20/32 or better. With mean logMAR (DCNVA and DCIVA) of 0.10±0.11 and 0.08±0.11, 88% had DCNVA/DCIVA of 20/40 or better. The defocus curve showed 0.2 logMAR or better visual acuity from -1.0 D to +1.0 D. Corneal HOAs were 1.62 µm at 6 mm, 0.45 at 4 mm, and 0.08 at 2 mm. The ocular HOAs were 0.07 µm.

Conclusion: Eyes having prior corneal irregularities with small-aperture IC-8 IOL demonstrated low ocular HOAs, thereby yielding good visual outcomes at all distances.

Purpose: To evaluate the impact of ELIOS combined with cataract surgery on ocular hypotensive medication burden in POAG pts at 24-mo.

Methods: Prospective clinical trial at 20 US sites (NCT04899063). Medication burden was assessed as proportion of patients on ocular hypotensive medications by visit and change from baseline. Ocular adverse events, VF and postoperative BCVA were assessed through the follow-up period.

Results: A total of 289 subjects available for 23mo analysis were included (mean age of 70 years). Mean preoperative number of ocular hypotensive medications was 1.5±0.7. Mean medication burden decreased to 0.3±0.8 at Month 23, corresponding to a mean change of -1.1±0.9. 82% of subjects were medication free at Month 23. At 24 months, VF Mean Deviation remained stable and 98.3% of pts achieved BCVA ≥20/32.

Conclusion: These findings suggest that ELIOS reduced medication burden in patients with mild to moderate open-angle glaucoma undergoing cataract surgery.

Purpose: To assess the 24-mo outcomes of the excimer laser in reducing intraocular pressure (IOP) in patients (pts) with mild-to-moderate primary open-angle glaucoma (POAG) undergoing cataract surgery.

Methods: Prospective, non-randomized, US trial at 20 sites (NCT04899063). Pts were treated with Elios procedure (B+L). Co-primary effectiveness endpoints were ≥20% reduction in unmedicated diurnal IOP and mean change in DIOP at Month 24. Safety was also assessed.

Results: A total of 318 pts underwent the procedure (mean age 70 years). At 24-mo, 76.1% of patients achieved a ≥20% decrease in unmedicated IOP, mean IOP change was −7.35 mmHg and mean±SD meds decreased from 1.5±0.7 to 0.3±0.8. Most ocular AEs were mild to moderate and occurred within Month 1. Endothelial cell density stabilized by Month 3, similar to phaco alone, and visual field parameters remained stable.

Conclusions: Both co-primary effectiveness endpoints were met, demonstrating sustained and clinically meaningful reductions in unmedicated diurnal IOP, decreased medication burden, and a favorable safety profile.

Purpose: Evaluating visual and refractive outcomes after bilateral Aspire intraocular lens (IOL) implantation.

Methods: Cataract patients ≥22 years with corrected distance visual acuity (CDVA) of 20/40 or worse and a projected CDVA of 20/30 or better received Aspire IOLs bilaterally (toric/non-toric). Binocular uncorrected, corrected, and distance-corrected visual acuities at far and intermediate (UDVA, UIVA, CDVA, DCIVA) were evaluated.

Results: With a mean postoperative MRSE of -0.18±0.37 D, Aspire IOL-implanted patients (n=310) achieved mean binocular UDVA and UIVA of 0.02±0.10 and 0.20±0.15 logMAR, respectively. Most subjects (90.6%) had binocular UDVA of 20/25 or better and 70.9% of subjects had UIVA of 20/32 or better. Mean binocular CDVA and DCIVA were -0.03±0.07 and 0.23±0.16 logMAR, respectively, with DCIVA of 20/32 or better in 64.4% of patients.

Conclusion: Bilateral implantation of Aspire IOL yielded good distance and intermediate visual acuity.

Purpose: To assess the impact of concomitant use of perfluorohexyloctane ophthalmic solution (PFHO) during contact lens wear.

Methods: In this phase 4, multicenter, prospective, open-label study, habitual wearers of soft, frequent-replacement contact lenses instilled PFHO bilaterally 4 times daily (1 time before, 3 times while wearing lenses) for 30 days. The primary outcome measure was the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8; maximum score: 37).

Results: In 104 enrolled patients (female, 79.8%; age range, 18–67 years), mean (SD) CLDEQ-8 score at baseline was 12.2 (6.6). Mean (SD) change from baseline was −2.8 (4.9) at Day 7, −3.8 (4.7) at Day 14, and −4.3 (5.8) at Day 30 (P<0.001). Total daily contact lens wear time, comfortable wear time, and end-of-day eye dryness were also significantly improved (P<0.001). No serious adverse events were reported; 1 patient (1.0%) discontinued PFHO due to adverse events (eye dryness, instillation discomfort).

Conclusion: PFHO use was well tolerated in contact lens wearers and was associated with improvements in patient-reported assessments of contact lens performance and tolerability.

For More Information:

Get Support

Contact Us

Contact a
Representative

Find My Local Rep link-out icon

Submit a
Medical Inquiry

Complete the Form